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ABSTRACT
Rhinocerebral mucormycosis is a potentially fatal and progressive angioinvasive fungal infection. It is classically 
described in patients with uncontrolled diabetes mellitus and hematological malignancies. This report describes a 
case of progressive rhinocerebral mucormycosis in a patient with poorly controlled diabetes who was on prolonged 
prednisolone therapy for autoimmune kidney disease. The patient, who was a female, presented to hospital with 
headache, orbital pain and nasal bridge swelling. Black eschar on nasal mucosae was present on admission. Later, 
she was started on intravenous fluconazole for the diagnosis of fungal sinusitis. Subsequently, she developed intra-
cerebral haemorrhage complicated with transtentorial herniation. Diagnosis of rhinocerebral mucormycosis was 
later observed by a laboratory finding and the treatment was changed to intravenous amphotericin B. However, the 
patient succumbed to her illness on the 6th day of hospitalisation. This report discusses the risk factors associated with 
rhinocerebral mucormycosis as well as the underlying pathogenesis. This report will also highlight the importance of 
early diagnosis and appropriate treatment for mucormycosis to improve prognosis in patients.
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INTRODUCTION
Mucormycosis is frequently a life-threatening infection 
caused by one of the members of Mucoraceae family, 
including Lichtheimia, Mucor and Rhizopus sp. The 
mortality rate of mucormycosis remains high between 
the range of 24% to 49% despite surgical management 
and appropriate antifungal therapy (1). Spectrum of 
mucormycosis ranges from cutaneous, rhinocerebral, 
and sinopulmonary to disseminated (2). Classically, 
these infections occur in individuals with altered 
host defense and those that have been associated 
with uncontrolled diabetes mellitus with or without 
ketoacidosis, neutropenia, treatment with corticosteroid, 
organ and bone marrow transplants, trauma and burns, 
malignant haematological diseases, iron overload, and 
deferoxamine therapy (3). As mucormycosis is a rapidly 
progressive infection, failure to recognise and delay in 
treatment of this fungal infection will increase the risk of 
adverse clinical outcomes.  
CASE REPORT
A 52-year-old female patient was presented to the 
Emergency Department with a chief complaint of facial 
pain and swelling over the nasal bridge and periorbital 
region for one week. It was associated with headache, 
fever and lethargy. Her medical history revealed that 
she had type 2 diabetes mellitus, hypertension and 
autoimmune kidney disease for five years. She was also 
on prednisolone for the past one year for autoimmune 
kidney disease.
On examination, there was a diffuse erythematous facial 
swelling over the nasal bridge extending bilaterally to 
the maxillary and infraorbital regions. On palpation, the 
swelling was tender and soft in consistency. Both eye 
movements were normal, and the pupils were reactive. 
There was no diplopia, ptosis, and proptosis. Endoscopic 
examination of nasal cavity revealed a presence of black 
crust at the inferior turbinate and vestibule, medial 
turbinate, and septum of the right nasal cavity. The left 
nasal cavity was unable to be visualised due to severe 
congestion. No abnormality was detected from the oral 
cavity examination. Examination of other body systems 
was unremarkable.
Vital signs upon presentation were otherwise normal. 
Laboratory investigation on admission demonstrated 
leukocytosis with neutrophilia (white cell counts 
21.9 × 109/L, neutrophils 74%), uncompensated 
metabolic acidosis (pH 7.317, HCO3- 20.8, lactate 1.4), 
hyperglycaemia (random blood glucose 16.8mmol/L), 
and glycosuria. However, diabetic ketoacidosis was 
unlikely because ketone was not detected. Blood urea 
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nitrogen was 38.8 mmol/L, and creatinine 460 µmol/L. 
Her coagulation tests were within the normal limits. 
Based on the history and clinical findings, a provisional 
diagnosis of fungal sinusitis was made, followed by the 
empirical therapy with intravenous fluconazole 200 mg 
once daily. 
Computed tomography (CT) scan revealed the mucosal 
thickening of bilateral frontal, ethmoid and maxillary 
sinuses, thickening of left eye preseptal soft tissue, 
and deviation of nasal septum to the left. The brain 
parenchyma was normal, and no focal-enhancing lesion 
found. Subsequently, endoscopic sinus surgery was 
done. Intraoperatively, there was an extensive fungal 
sinusitis involving nasal cavity, septum and all paranasal 
sinuses with pus and black eschar. The lesion was 
extending into the base of the skull at bilateral orbital 
lamina of ethmoid bone. Removal of necrotic tissue and 
debridement of sinus cavity were performed. Pus and 
tissue sample were sent to the microbiology laboratory. 
Fungal culture grew mould after a-three day incubation 
period. Based on macroscopic and microscopic 
characteristics, it was identified as Rhizomucor sp. 
(Fig.1). However, no confirmation test by molecular 
method was done. Following the microbiology result, 
the antifungal agent was changed from fluconazole to 
intravenous amphotericin B.
Figure 2: Urgent Computed tomography of brain. Large left 
fronto-temporo-parietal extraxial hematoma, midline shift and 
cerebral oedema.
transtentorial herniation and worsening of pansinusitis 
(Fig.2). She passed away within 24 hours after the event. 
DISCUSSION
The most common genus associated with mucormycosis 
are those of genera Rhizopus sp, Lichtheimia and Mucor 
(2). The incidence rate of rhinocerebral mucormycosis 
was reported as 1.7 cases per million people per year 
in the United States (2). Although mucormycosis can 
manifest in a variety of clinical forms, rhinocerebral 
mucormycosis found is predominantly associated in 
patients with poorly controlled diabetes mellitus and 
diabetic ketoacidosis (2). Diabetes mellitus was found to 
be the underlying illness in about 66% of patients with 
rhinocerebral mucormycosis (4).
When infected, the phagocytes will move towards 
and kill the microorganism by oxidative as well as 
nonoxidative mechanisms. This ability is impaired in 
patients with hyperglycemia and acidosis. Other than 
that, patients with systemic acidosis have elevated level 
of available serum iron. Low pH state will cause proton-
mediated displacement of ferric iron (Fe3+) from serum 
carrier molecules. Then, at the cell surface of mucorales, 
ferric iron (Fe3+) is reduced to ferrous iron (Fe2+). Iron is 
needed for the growth of mucorales in serum (3).
In this case, it was presumed that uncontrolled diabetes 
and prolonged prednisolone therapy have predisposed 
the patient to mucormycosis, particularly in rhinocerebral 
form. High glucose and iron concentrations will induce 
the expression of glucose-regulated protein 78 (GRP78). 
GRP78 was identified as the host receptor in endothelial 
cells which mediates the invasion and damage of human 
endothelial cells (3).
Rhinocerebral mucormycosis is believed to have 
begun with the inhalation of spores into paranasal 
sinuses of susceptible host. The infection usually 
manifests as acute sinusitis. Patient often complains 
of nasal congestion, fever, headache, sinus pain, and 
Figure 1: Photomicrograph of Lactophenol cotton blue 
stained of fungal colony (magnification x 400). Rhizomucor 
sp.was identified.
However, despite the change of antifungal therapy, 
the patient’s condition worsened with GCS E2M1VT. 
Urgent computed tomography scan of the brain and 
paranasal sinuses revealed new large fronto-temporo-
parietal extra-axial hematoma with acute bleed 
component, causing significant mass effect, midline 
shift and cerebral oedema. There was also evidence of 
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purulent nasal discharge. After all sinuses are affected, 
the infection will spread to the contagious structures, 
such as orbit, palate and brain (2). The angioinvasion 
properties of mucorales which causes purulent arteritis 
and thrombosis, can result in fatal strokes, and patient 
can present with acute subdural hematoma, massive 
intracerebral haemorrhage, and basal ganglia bleed (2).
The patient in this case study displayed no signs of central 
nervous system involvement on initial presentation. 
Infection might be rapidly progressed and directly 
spread, involving central nervous system in a few days, 
that resulted in intracerebral haemorrhage complication 
with transtentorial herniation.
Surgical debridement is strongly recommended to 
be combined with antifungal therapy in patient with 
mucormycosis. There are two systemic antifungal 
therapies currently available with good activity 
toward mucormycosis: amphotericin B and triazole 
posaconazole. However, the use of amphotericin B 
deoxycholate is discouraged due to its toxicity (1). 
Meanwhile, the posaconazole has enhanced in vitro 
activity against mucormycosis (1).
There was a delay in proper treatment of mucormycosis 
in this case. An initial diagnosis of fungal sinusitis 
was established, and patient was treated empirically 
with intravenous fluconazole which has no reliable 
activity against mucormycosis (1). Early recognition 
of mucormycosis and rapid initiation of appropriate 
antifungal therapy together with surgical debridement 
are important in improving patient survival before 
angioinvasion, necrosis and dissemination of 
mucormycosis to other organs (5).
Underlying poorly controlled diabetes mellitus and 
black eschar during endoscope examination and 
surgery should prompt a high index of suspicion for 
mucormycosis and treatment with proper antifungal 
therapy should begin without waiting for the culture 
result. For this patient, early administration of appropriate 
antifungal therapy combined with surgical debridement 
might have prevented the progression of mucormycosis 
into her central nervous system.
CONCLUSION
Mortality rate of rhinocerebral mucormycosis is high 
despite the surgical debridement and antifungal therapy. 
Underlying comorbidities, clinical features, and physical 
examination of patient should prompt a high index of 
suspicion for mucormycosis. In conclusion, clinician’s 
awareness, early initiation of appropriate antifungal 
agent, and surgical intervention represent the effective 
management of mucormycosis.
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